Instruments and new technologies for the in vivo diagnosis of melanoma - 29/08/11
Abstract |
The principal objective of screening individuals at risk for melanoma is detection of cutaneous melanoma during the curable stages of its early evolution. Unaided visual inspection of the skin is often suboptimal at diagnosing melanoma. Improving the diagnostic accuracy for melanoma remains an area of active research. These research efforts have focused on both the detection of early melanoma and the in-depth evaluation of suspicious pigmented lesions for the presence or absence of melanoma. Numerous instruments are under investigation to determine their usefulness in imaging and ascertaining a correct in vivo diagnosis of melanoma. It is anticipated that some of these tools, alone or in combination, will improve our ability to differentiate, in vivo, melanoma from its simulators. Ultimately, these advances may prevent unnecessary biopsies (increased specificity) while increasing the sensitivity for diagnosing melanoma. This article reviews the current instruments and new technologies for the in vivo diagnosis of melanoma.
Learning objective |
At the conclusion of this learning activity, participants should be acquainted with the instruments designed to facilitate the early detection of melanoma. They should also be familiar with the basic technology behind these instruments and should recognize the potential benefits and limitations inherent in each.
Le texte complet de cet article est disponible en PDF.Plan
Supported by the Ronald O. Perelman Department of Dermatology, New York University School of Medicine; Joseph M. Hazen Foundation; Mary and Emanuel Rosenthal Foundation; Kaplan Comprehensive Cancer Center (Cancer Center Support Core Grant No. 5P30-CA-16087); Blair O. Rogers Medical Research Fund; the Rahr Family Foundation; and Stavros S. Niarchos Foundation Fund of The Skin Cancer Foundation. Disclosure: Dr Kopf is involved with the development of the Melafind equipment with Electro-Optical Sciences, Inc (Irvington, NY), but has not received any personal remuneration from this work. Dr Swindle had a research consultation role with Optiscan Pty Ltd (Australia) within the last 5 years. |
Vol 49 - N° 5
P. 777-797 - novembre 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?